Table 2.

Fas, FasL, and CASP8 allelic and genotype frequencies among patients and controls and their association with pancreatic cancer risk

GenotypePatients (n = 397), n (%)Controls (n = 907), n (%)OR* (95% CI)P
Fas −1377G→A
    GG186 (46.9)420 (46.3)1.00 (Reference)
    AG169 (42.6)376 (41.5)1.06 (0.82-1.37)0.642
    AA42 (10.5)111 (12.2)0.86 (0.58-1.28)0.447
A allele frequency0.320.33
Ptrend0.590
Fas −670A→G
    AA158 (39.8)357 (39.4)1.00 (Reference)
    AG182 (45.8)419 (46.2)0.98 (0.75-1.27)0.858
    GG57 (14.4)131 (14.4)0.99 (0.69-1.43)0.971
G allele frequency0.370.38
Ptrend0.890
FasL −844C→T
    CC238 (59.9)451 (49.7)1.00 (Reference)
    CT144 (36.3)377 (41.6)0.73 (0.57-0.94)0.015
    TT15 (3.8)79 (8.7)0.35 (0.19-0.63)<0.001
T allele frequency0.220.30
Ptrend<0.0001
CASP8 −652 6N ins→del
    ins/ins268 (67.5)521 (57.4)1.00 (Reference)
    ins/del111 (28.0)323 (35.6)0.65 (0.50-0.85)0.002
    del/del18 (4.5)63 (7.0)0.56 (0.33-0.98)0.041
    del allele frequency0.190.25
Ptrend0.0007
  • * Data were calculated by logistic regression, adjusted for age, sex, smoking, drinking, and diabetes mellitus history.

  • Tests for trend of odds were two sided and based on likelihood ratio tests assuming a multiplicative model.